Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a simple device keep blood flowing and prevent dangerous clots?

NCT ID NCT05469282

Disease control Sponsor: Ceragem Clinical Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed trial tested a device called Ceragem Master V6 to see if it improves blood circulation in people at risk for deep vein thrombosis (DVT) and in healthy adults. 59 participants used the device once, and researchers measured changes in blood flow speed and vein size using ultrasound. The goal was to see if the device could help prevent blood clots by improving circulation.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Ceragem Master V6 (blood circulation device)
What this could lead to
If it works, this device could help improve blood flow and reduce the risk of deep vein thrombosis (DVT) in people at risk.
What could go wrong
This is a small, early-stage trial with only 59 participants and no comparison group, so results may not apply widely. The device is already on the market, so the benefit over standard care is unclear.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

59 people

The number who actually took part.

Started

Aug 2022

Finished

Dec 2022

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

19 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria for all subjects; 1. Adult men and women over 19 years of age 2. Subjects who have not been diagnosed with deep vein thrombosis in the lower extremities through the following test results prior to the application of medical devices. 1. Subjects diagnosed by Doppler ultrasonography as having no blood clots in the femoral vein and the vena poplitea 2. D-dimer negative test result (Even if the D-dimer test is positive, the subject can be selected through the additional test at the discretion of investigator.) 3\. Subjects who fully understand the purpose and procedure of the study and wish to participate in clinical trials with voluntary consent Additional Inclusion Critetia for the DVT risk subjects; 1\. Subjects have two or more points of venous thromboembolism (hereinafter referred to as VTE) clinical prediction score (Two-level wells scroe) at the time of screening Exclusion Criteria: 1. Subjects who complain of a decrease in the sensation of the lower extremities or who is unable to feel the sensation of pain 2. Subjects who have inflammation or trauma on the skin that directly touches the device

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Blood circulation disorder are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

vascular disorder venous thromboembolism Venous Thrombosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Blood circulation disorder Deep vein thrombosis

Contacts and locations

Locations

  • Presbyterian Medical Center

    Jeonju, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.